North Shore Uranium Ltd. (TSXV:NSU)(OTCQB:NSURF) ("North Shore" or the "Company") is pleased to provide an update on its ...
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial ...
"We are executing with urgency and purpose as we advance our pipeline assets to the clinic as expeditiously as possible," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "We are ...
Climate Action Forum (CAF) has convened its fourth high-level Steering Committee meeting, reaffirming its commitment to ...
Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic ...
VANCOUVER, BC / ACCESS Newswire / April 9, 2026 / North Shore Uranium Ltd. (TSXV:NSU)(OTCQB:NSURF) ("North Shore" or the ...
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trialCAMBRIDGE, Mass., April 7, 2026 ...
Black Book Research, in its 2026 research series on payer IT, software, and services, reports that data usability, workflow activation, identity confidence, and provenance gaps, rather than transport ...
Discover the top 3 undervalued Energy Equipment & Services stocks for Friday, April 10 based on AAII’s Stock Grades.
Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.
The Committee recommends shifting from entity-level to project-wise insolvency to avoid delays and protect viable projects. It held that completion, not liquidation, should be the primary objective in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results